Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Natural history, survival, and mortality
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

4 evidence topics · 2 sources

Untreated disease course

“Prior to the anti-VEGF era, the clinical manifestation of the natural history of nAMD was the formation of a disciform scar and blindness” (opens the source at this quote in a new tab)
“AMD leads to blindness when left untreated, due to the development of atrophy and/or disciform scar.” (opens the source at this quote in a new tab)

Magnitude of untreated vision loss

“ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.” (opens the source at this quote in a new tab)

Scarring despite treatment

“Scar tissue was detected in approximately half of the patients after two years of intensive treatment” (opens the source at this quote in a new tab)

Contribution to overall disease burden

“While less common than dry AMD, wet or nvAMD accounts for almost 90% of blindness associated with AMD.” (opens the source at this quote in a new tab)

Mortality attributable to neovascular AMD

No evidence found.